Full-Time

Pipeline Chief of Staff

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Senior, Expert

Somerset County, NJ, USA

This position requires being onsite 3 days a week.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor degree in science with 15 years of industry experience and demonstrated leadership in project and/or operational management. Master degree in science preferred.
  • 15+ years of industry experience in a biotech or pharmaceutical setting, including 5 years of industrial experience in pipeline project and operational management.
  • Demonstrated experience interacting with executive leadership.
  • Experience gathering and integrating inputs from all disciplines in the company to facilitate assessments, planning and strategy by the pipeline executive team. Able to help bring these inputs up to an appropriately high level to facilitate effective high-level communications, analysis and decision making.
  • Strong holistic approach to working with groups of high-performance individuals. Able to pull the best from teams while at the same time being able to contribute and help synthesize.
  • High EQ with ability to earn the respect and trust of the pipeline team, President, executive leadership, and board.
  • Ability to work effectively in a collaborative, fast-paced environment with competing priorities while also making a strong personal impact.
  • Ability to set and follow through goals with a sense of urgency while keeping broader strategic objectives in focus and delivering high standard outcomes.
  • Exceptional interpersonal skills.
  • Excellent planning, prioritization, and organizational skills.
  • Excellent communication skills, verbal, graphical, and written, with a keen sense of how to connect with people and build trust.
  • Effective presentation skills to key stakeholders and key decision makers.
  • Excellent taste when it comes to communications work products.
  • Working experience in drug discovery and development and good understanding of external landscape in relevant disease areas.
  • Creative, strategic thinking, operational effectiveness, and strong troubleshooting skills
  • Collaborative attitude and ability to motivate and influence others without relying on position or power.
  • Language(s): English. Mandarin is a plus.
Responsibilities
  • Organize efforts across the organization as needed to provide timely and reliable information to support pipeline planning and communications. Enable effective and rapid decision making with clear risks, mitigations, go/no-go criteria as part of a holistic operational plan to achieve success.
  • Ensure integration of pipeline project dashboard and help monitor performance of organization as a whole in collaboration with the PMO. Contribute to portfolio vision and prioritization.
  • Manage meetings with key stakeholders and other senior leaders, including President’s Sr Staff Meetings, Pipeline Update Meetings, Quarterly Pipeline Townhall, etc.
  • Assist leading the pipeline organization in pivots in response to emerging data, evolution of the competitive landscape, company priorities, etc.
  • Collaborate with functional leaders and experts as a strategic partner to support the success of Legend programs.
  • Build strong collaborative relationships with functional areas and creates a culture of transparency, unity and engagement.
  • Track and manage tasks delegated by President to staff across the organization to ensure timely completion.
  • Prepare materials for communications with the organization, including meeting materials and regular updates. Track action plan to ensure timely delivery.
  • Work with pipeline leadership in developing and communicating overarching pipeline strategy and plan.
  • Work with pipeline leadership to identify and resolve inter-project bottlenecks as well as identify and leverage synergy opportunities.
  • Work with pipeline leadership in developing corporate goals and ensuring alignment of cascading goals across the business.
  • Monitor and analyze resource and capital allocation across the department to align with pipeline strategy and plan.
  • Identify potential operating efficiencies and help drive for solutions.
  • Lead special projects to support pipeline decision making, often requiring inputs from multiple branches of the organization, including analysis of operating efficiencies.
  • Interface with other corporate functions, including Finance, HR, IT, and Legal.
  • Support ad hoc corporate opportunity analysis and decisions.
  • Perform other strategic analyses and projects as needed.
Desired Qualifications
  • Master degree in science preferred.
  • Mandarin is a plus.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Multiply Labs could enhance manufacturing efficiency through automation.
  • European Commission's approval of CARVYKTI® expands market reach in multiple myeloma treatment.
  • New R&D facility in Philadelphia may lead to breakthroughs in next-generation cell therapies.

What critics are saying

  • Competition from Amgen's Imdelltra may impact market share in oncology.
  • Expansion into Philadelphia R&D facility could strain financial resources if mismanaged.
  • Dependency on MaxCyte's technology poses risks if MaxCyte faces operational issues.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.